Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Working Capital Changes (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Working Capital Changes for 6 consecutive years, with -$190000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 93.04% to -$190000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$757000.0, a 34.29% increase, with the full-year FY2025 number at -$757000.0, up 34.29% from a year prior.
  • Other Working Capital Changes was -$190000.0 for Q4 2025 at Lexicon Pharmaceuticals, down from $239000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $2.7 million in Q2 2024 to a low of -$2.7 million in Q4 2024.
  • A 3-year average of $82500.0 and a median of -$176000.0 in 2024 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 289.85% in 2024; the steepest drop was 382.99% in 2024.
  • Lexicon Pharmaceuticals' Other Working Capital Changes stood at $964000.0 in 2023, then tumbled by 382.99% to -$2.7 million in 2024, then soared by 93.04% to -$190000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Other Working Capital Changes are -$190000.0 (Q4 2025), $239000.0 (Q3 2025), and -$620000.0 (Q2 2025).